Crossmark

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia

Published Online: 2024-11-13

Published Print: 2025-02

Authors

Christopher, Mary R. https://orcid.org/0000-0003-4723-9118
Nawas, Mariam T.

Reagan, John L.
License Information

Text and Data Mining valid from 2024-11-13

Version of Record valid from 2024-11-13
More Information

Article History

Received: 17 June 2024

Revised: 30 October 2024

Accepted: 1 November 2024

First Online: 13 November 2024

Competing interests

: MRC and MTN have no disclosures. JLR reports serving as a consultant and/or advisory board member for Sanofi and Bristol Myers Squibb; research support from Pfizer.

Document is current